Friday, 6 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 22, 2026

Procter & Gamble posts earnings beat: CFO on the results

View original at finance.yahoo.com
Procter & Gamble posts earnings beat: CFO on the results Procter & Gamble (PG) reported adjusted earnings of $1.88 per share and revenue of $22.2 billion for its fiscal second quarter…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • US had weak shipment quarter due to significant inventory build in base year from two port strikes and hurricane about a year ago

    80% confidence
  • Tariff exposure reduced from $1 billion at beginning of year to $400 million after tax

    80% confidence
  • P&G consumption in US over last three months would have been 1.5% to 2% in value terms excluding pantry loading

    80% confidence
  • Gillette is one of P&G's most profitable businesses from an operating margin perspective

    80% confidence
  • Innovation capabilities across biology, chemistry, fiber technology, assembled products, and electronics have never been stronger

    80% confidence
  • P&G reduced tariff exposure through productivity work, sourcing changes, formulation changes, and innovation-based pricing

    80% confidence
  • If base effect of inventory loading is removed, US would have already shown growth

    80% confidence
  • Typical category growth rate is 3-4%, and current 1-2% growth is slower than normal

    80% confidence
  • P&G firmly believes categories will return to 3-4% growth over time

    80% confidence
  • P&G offers three tiers of diapers: Swaddlers (super premium), Baby Dry (mid-tier), and Luvs (value tier close to private label pricing)

    80% confidence
  • P&G categories in US have grown between 1-2% in value growth and flat in volume growth over past three months

    80% confidence
  • Six figure jobs are being created from AI data centers

    80% confidence
  • US economy is growing at 4-5% and could continue at that growth rate

    80% confidence
  • Business outside the US is growing 3% with Latin America at 8%, China at 3%, Europe at 3%, and Asia/Africa at 2%

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com
Procter & Gamble posts earnings beat: CFO on the results — Source | Via News | ViaNews EU